2021 Venture Investment Was Bullish – Will 2022 Be The Same?
The VC market during 2021 was frantic, cash rich and oftentimes appeared to be acting on a “buy now, ask questions later” mentality. With COVID headwinds dwindling, and emerging market uncertainties, what will 2022 bring?
You may also be interested in...
Zimmer Biomet Spin-Off’s Share Price Plummets
The share price for ZimVie, Zimmer Biomet’s spinal and dental spin-off company, dropped following its launch on NASDAQ.
Finance Watch: IPOs At A Standstill As US Biotech Stock Valuations Plummet
There have been no biopharma initial public offerings in the US since 12 January while the industry’s valuations have plummeted by double digits since the start of 2022. Nevertheless, venture capital investment continues at a fast pace and there have been some follow-on public offerings.
Neumora Launches With $500m To Advance Personalized Neuroscience Drugs
Combining biological insights with data science, the start-up emerges from stealth mode after two years of assembling its technology platform and R&D pipeline based on internal and external know-how.